Structure-guided engineering of Anticalins with improved binding behavior and biochemical characteristics for application in radio-immuno imaging and/or therapy

Journal of Structural Biology

Volumn 185, Issue 2, 2014, Pages 203-214

  Eggenstein, E ^a   Eichinger, A ^a   Kim, H J ^a   Skerra, A ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Crystal structure; Lipocalin; Metal binding; Protein engineering; Rational design

Indexed keywords

CRYSTAL STRUCTURE; LIPOCALIN; METAL BINDING; PROTEIN ENGINEERING; RATIONAL DESIGN;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; BINDING SITES; CHELATING AGENTS; CRYSTALLOGRAPHY, X-RAY; DIRECTED MOLECULAR EVOLUTION; LIPOCALINS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; PENTETIC ACID; PROTEIN BINDING; PROTEIN STABILITY; RADIOPHARMACEUTICALS; SOLUBILITY; YTTRIUM;

EID: 84894986114     PISSN: 10478477     EISSN: 10958657     Source Type: Journal    
DOI: 10.1016/j.jsb.2013.03.009     Document Type: Article

References (61)

1. HER2:2395, with C-terminally engineered cysteine. J. Nucl. Med. 2009, 50:781-789.
2. Åkerström B., Borregaard N., Flower D.A., Salier J.-S. Lipocalins 2006, Landes Bioscience, Georgetown, Texas.
3. Boswell C.A., Brechbiel M.W. Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view. Nucl. Med. Biol. 2007, 34:757-778.
4. Breustedt D.A., Schönfeld D.L., Skerra A. Comparative ligand-binding analysis of ten human lipocalins. Biochim. Biophys. Acta 2006, 1764:161-173.
5. Brunger A.T. Free R value: cross-validation in crystallography. Methods Enzymol. 1997, 277:366-396.
6. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 1994, 50:760-763. CCP4.
7. Corneillie T.M., Whetstone P.A., Fisher A.J., Meares C.F. A rare earth-DOTA-binding antibody: probe properties and binding affinity across the lanthanide series. J. Am. Chem. Soc. 2003, 125:3436-3437.
8. DeLano W.L. The PyMOL Molecular Graphics System 2002, DeLano Scientific.
9. Dougherty D.A. Cation-π interactions in chemistry and biology: a new view of benzene, Phe, Tyr, and Trp. Science 1996, 271:163-168.
10. Emsley P., Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 2004, 60:2126-2132.
11. Fersht A. Structure and Mechanism in Protein Science: A Guide to Enzyme Catalysis and Protein Folding 1998, W.H. Freeman, New York.
12. Fling S.P., Gregerson D.S. Peptide and protein molecular weight determination by electrophoresis using a high-molarity tris buffer system without urea. Anal. Biochem. 1986, 155:83-88.
13. Flower D.R. The lipocalin protein family: structure and function. Biochem. J. 1996, 318:1-14.
14. Fujita H., Yamagishi M., Kida Y., Sakaguchi M. Positive charges on the translocating polypeptide chain arrest movement through the translocon. J. Cell Sci. 2011, 124:4184-4193.
15. Gasteiger E., Gattiker A., Hoogland C., Ivanyi I., Appel R.D., et al. ExPASy: The proteomics server for in-depth protein knowledge and analysis. Nucleic Acids Res. 2003, 31:3784-3788.
16. Gebauer M., Skerra A. Engineered protein scaffolds as next-generation antibody therapeutics. Curr. Opin. Chem. Biol. 2009, 13:245-255.
17. Gebauer M., Skerra A. Anticalins: small engineered binding proteins based on the lipocalin scaffold. Methods Enzymol. 2012, 503:157-188.
18. Gebauer M., Schiefner A., Matschiner G., Skerra A. Combinatorial design of an Anticalin directed against the extra-domain B for the specific targeting of oncofetal fibronectin. J. Mol. Biol. 2013, 425:780-802.
19. Goetz D.H., Holmes M.A., Borregaard N., Bluhm M.E., Raymond K.N., et al. The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol. Cell 2002, 10:1033-1043.
20. Goldenberg D.M., Sharkey R.M., Paganelli G., Barbet J., Chatal J.F. Antibody pretargeting advances cancer radioimmunodetection and radioimmuno-therapy. J. Clin. Oncol. 2006, 24:823-834.
21. Goldenberg D.M., Chang C.H., Rossi E.A., McBride W.J. Pretargeted molecular imaging and radioimmunotherapy. Theranostics 2012, 2:523-540.
22. Holliger P., Hudson P.J. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 2005, 23:1126-1136.
23. Hooft R.W., Vriend G., Sander C., Abola E.E. Errors in protein structures. Nature 1996, 381:272.
24. Katsamba P.S., Navratilova I., Calderon-Cacia M., Fan L., Thornton K., et al. Kinetic analysis of a high-affinity antibody/antigen interaction performed by multiple Biacore users. Anal. Biochem. 2006, 352:208-221.
25. Kaur S., Venktaraman G., Jain M., Senapati S., Garg P.K., et al. Recent trends in antibody-based oncologic imaging. Cancer Lett. 2012, 315:97-111.
26. Kenanova V., Wu A.M. Tailoring antibodies for radionuclide delivery. Expert Opin. Drug Deliv. 2006, 3:53-70.
27. Kim H.J., Eichinger A., Skerra A. High-affinity recognition of lanthanide(III) chelate complexes by a reprogrammed human lipocalin 2. J. Am. Chem. Soc. 2009, 131:3565-3576.
28. Koide S. Design and engineering of synthetic binding proteins using nonantibody scaffolds. Protein Engineering and Design 2010, 109-130. CRC Press, Boca Raton, Florida. S.J. Park, J.R. Cochran (Eds.).
29. Krissinel E., Henrick K. Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 2007, 372:774-797.
30. Langer G., Cohen S.X., Lamzin V.S., Perrakis A. Automated macromolecular model building for X-ray crystallography using ARP/wARP version 7. Nat. Protoc. 2008, 3:1171-1179.
31. Laskowski R.A., Macarthur M.W., Moss D.S., Thornton J.M. Procheck - a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 1993, 26:283-291.
32. Löfblom J., Feldwisch J., Tolmachev V., Carlsson J., Ståhl S., et al. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett. 2010, 584:2670-2680.
33. Love R.A., Villafranca J.E., Aust R.M., Nakamura K.K., Jue R.A., et al. How the anti-(metal chelate) antibody CHA255 is specific for the metal ion of its antigen: X-ray structures for two Fab'/hapten complexes with different metals in the chelate. Biochemistry 1993, 32:10950-10959.
34. McCoy A.J., Grosse-Kunstleve R.W., Adams P.D., Winn M.D., Storoni L.C., et al. Phaser crystallographic software. J. Appl. Crystallogr. 2007, 40:658-674.
35. Miao Z., Levi J., Cheng Z. Protein scaffold-based molecular probes for cancer molecular imaging. Amino Acids 2011, 41:1037-1047.
36. Milenic D.E., Brady E.D., Brechbiel M.W. Antibody-targeted radiation cancer therapy. Nat. Rev. Drug Discov. 2004, 3:488-499.
37. Myszka D.G. Improving biosensor analysis. J. Mol. Recognit. 1999, 12:279-284.
38. Orcutt K.D., Slusarczyk A.L., Cieslewicz M., Ruiz-Yi B., Bhushan K.R., et al. Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging. Nucl. Med. Biol. 2011, 38:223-233.
39. Pan H., Chen K., Chu L., Kinderman F., Apostol I., et al. Methionine oxidation in human IgG2 Fc decreases binding affinities to protein A and FcRn. Protein Sci. 2009, 18:424-433.
40. Pettersen E.F., Goddard T.D., Huang C.C., Couch G.S., Greenblatt D.M., et al. UCSF Chimera - a visualization system for exploratory research and analysis. J. Comput. Chem. 2004, 25:1605-1612.
41. Raymond K.N., Dertz E.A., Kim S.S. Enterobactin: an archetype for microbial iron transport. Proc. Natl. Acad. Sci. USA 2003, 100:3584-3588.
42. Reichert J.M. Antibody-based therapeutics to watch in 2011. MAbs 2011, 3:76-99.
43. Sato N., Hassan R., Axworthy D.B., Wong K.J., Yu S., et al. Pretargeted radioimmunotherapy of mesothelin-expressing cancer using a tetravalent single-chain Fv-streptavidin fusion protein. J. Nucl. Med. 2005, 46:1201-1209.
44. Schlehuber S., Skerra A. Duocalins: engineered ligand-binding proteins with dual specificity derived from the lipocalin fold. Biol. Chem. 2001, 382:1335-1342.
45. Schlehuber S., Skerra A. Tuning ligand affinity, specificity, and folding stability of an engineered lipocalin variant - a so-called 'anticalin' - using a molecular random approach. Biophys. Chem. 2002, 96:213-228.
46. Schlehuber S., Beste G., Skerra A. A novel type of receptor protein, based on the lipocalin scaffold, with specificity for digoxigenin. J. Mol. Biol. 2000, 297:1105-1120.
47. Schmidt T.G., Skerra A. The Strep-tag system for one-step purification and high-affinity detection or capturing of proteins. Nat. Protoc. 2007, 2:1528-1535.
48. Schönfeld D., Matschiner G., Chatwell L., Trentmann S., Gille H., et al. An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies. Proc. Natl. Acad. Sci. USA 2009, 106:8198-8203.
49. Shapovalov M.V., Dunbrack R.L. A smoothed backbone-dependent rotamer library for proteins derived from adaptive kernel density estimates and regressions. Structure 2011, 19:844-858.
50. Sharkey R.M., Karacay H., Cardillo T.M., Chang C.H., McBride W.J., et al. Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods. Clin. Cancer Res. 2005, 11:7109s-7121s.
51. Sharkey R.M., Chang C.H., Rossi E.A., McBride W.J., Goldenberg D.M. Pretargeting: taking an alternate route for localizing radionuclides. Tumour Biol. 2012, 33:591-600.
52. 111In-labeled MORAb-009, an anti-mesothelin antibody. Nucl. Med. Biol. 2011, 38:1119-1127.
53. Skerra A. Lipocalins as a scaffold. Biochim. Biophys. Acta 2000, 1482:337-350.
54. Skerra A. Anticalins as alternative binding proteins for therapeutic use. Curr. Opin. Mol. Ther. 2007, 9:336-344.
55. Skerra A. Alternative non-antibody scaffolds for molecular recognition. Curr. Opin. Biotechnol. 2007, 18:295-304.
56. Skerra A. Alternative binding proteins: anticalins - harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities. FEBS J. 2008, 275:2677-2683.
57. Steiner M., Neri D. Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends. Clin. Cancer Res. 2011, 17:6406-6416.
58. EGFR:2377 Affibody molecule: aspect of the injected tracer amount. Eur. J. Nucl. Med. Mol. Imaging 2010, 37:613-622.
59. Tomblyn M. Radioimmunotherapy for B-cell non-hodgkin lymphomas. Cancer Control 2012, 19:196-203.
60. Vaughan T.J., Williams A.J., Pritchard K., Osbourn J.K., Pope A.R., et al. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat. Biotechnol. 1996, 14:309-314.
61. Weichenberger C.X., Sippl M.J. NQ-Flipper: recognition and correction of erroneous asparagine and glutamine side-chain rotamers in protein structures. Nucleic Acids Res. 2007, 35:W403-W406.